Press release
Mesothelioma Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | GSK, Merck, Bristol-Myers Squibb, AstraZeneca, Roche, Novartis, Pfizer Inc
"Mesothelioma Pipeline Insight, 2026 [https://www.delveinsight.com/sample-request/mesothelioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gaurav]" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Mesothelioma Market.
The Mesothelioma Pipeline report embraces in-depth commercial and clinical assessment of the pipeline products from the pre-clinical developmental phase to the marketed phase. The report also covers a detailed description of the drug, including the mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, collaborations, mergers acquisition, funding, designations, and other product-related details.
Some of the key takeaways from the Mesothelioma Pipeline Report:
*
Companies across the globe are diligently working toward developing novel Mesothelioma treatment therapies with a considerable amount of success over the years.
*
Mesothelioma companies working in the treatment market are The Netherlands Cancer Institute, Bristol-Myers Squibb, PrECOG, LLC., Memorial Sloan Kettering Cancer Center, ETOP IBCSG Partners Foundation, MedImmune LLC, Aslaug Helland, AstraZeneca, Oncotelic Inc., Hyogo Medical University, Trizell Ltd, RS Oncology LLC, Vivace Therapeutics, Inc, TCR2 Therapeutics, Sanofi, ImmVira Pharma Co. Ltd, TCR2 Therapeutics, CRISPR Therapeutics, Biotheus Inc., and others, are developing therapies for the Mesothelioma treatment
*
Emerging Mesothelioma therapies in the different phases of clinical trials are- Pembrolizumab, Nivolumab, Durvalumab, Sacituzumab govitecan-hziy, Carboplatin, Tremelimumab, ipilimumab, Volrustomig, OT-101, Lenvatinib, rAd-IFN, RSO-021, VT3989, gavo-cel, THOR-707, T3011, TC-510, CTX131, PM8002, and others are expected to have a significant impact on the Mesothelioma market in the coming years.
*
In May 2026, Researchers continued enrolling patients in clinical trials evaluating mesothelin-targeted CAR-T cell therapies, bispecific antibodies, and personalized immunotherapy strategies aimed at enhancing treatment outcomes for individuals with advanced mesothelioma.
*
In April 2026, The ATOMIC-Meso trial assessed the efficacy of weekly intramuscular pegargiminase in combination with pemetrexed and platinum-based chemotherapy compared with placebo plus chemotherapy in previously untreated patients with mesothelioma. The study represents one of the most advanced late-stage clinical development programs for the disease.
*
In January 2026, Multiple Phase I-III clinical trials investigating immunotherapies, targeted therapies, CAR-T cell therapies, and tumor-targeted agents continued to enroll patients with malignant pleural mesothelioma, reflecting sustained progress in the disease's therapeutic pipeline.
*
In August 2025, VT3989, a TEAD autopalmitoylation inhibitor, has been granted orphan drug designation by the FDA for treating adult mesothelioma patients, as announced by Vivace Therapeutics.
*
In July 2025, The U.S. FDA has awarded orphan drug designation to VT3989 for mesothelioma treatment in the United States, according to Vivace Therapeutics. VT3989 is an investigational therapy that inhibits palmitoylation in TEAD proteins, key components of the Hippo pathway, which regulates cell growth and division.
*
In April 2025, GSK's Zejula (niraparib) demonstrated a 27% reduction in the risk of disease progression or death in mesothelioma patients in an investigator-initiated Phase II trial. The NERO study (NCT05455424) evaluated Zejula's effectiveness in 88 mesothelioma patients who experienced relapse following prior platinum-based systemic therapy. The trial is sponsored by the University Hospital Southampton NHS Foundation Trust and funded by Asthma + Lung UK, with additional support from Mesothelioma UK and the Mavis Nye Foundation.
*
In January 2025, Insilico Medicine ("Insilico"), a clinical-stage AI-driven biotechnology company, has announced that the first patient has been dosed in its global multicenter Phase I trial of ISM6331, a novel pan-TEAD inhibitor developed using its AI-powered generative chemistry platform, Chemistry42. ISM6331 is being investigated for the treatment of mesothelioma and other solid tumors. Notably, it is Insilico's leading oncology program within its AI-driven drug discovery pipeline and has received Orphan Drug Designation (ODD) from the FDA for mesothelioma treatment.
Mesothelioma Overview
Mesothelioma is a type of cancer that develops from the thin layer of tissue that covers many of the internal organs (mesothelium). The most common form is pleural mesothelioma, which affects the lining of the lungs and is often associated with exposure to asbestos fibers. Other less common forms include peritoneal mesothelioma (affecting the lining of the abdomen), and pericardial mesothelioma (affecting the lining around the heart).
Get a Free Sample PDF Report to know more about Mesothelioma Pipeline Therapeutic Assessment-
https://www.delveinsight.com/report-store/mesothelioma-pipeline-insight [https://www.delveinsight.com/report-store/mesothelioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gaurav]
Emerging Mesothelioma Drugs Under Different Phases of Clinical Development Include:
*
Pembrolizumab: The Netherlands Cancer Institute
*
Nivolumab: Bristol-Myers Squibb
*
Durvalumab: PrECOG, LLC.
*
Sacituzumab govitecan-hziy: Memorial Sloan Kettering Cancer Center
*
Carboplatin: ETOP IBCSG Partners Foundation
*
Tremelimumab: MedImmune LLC
*
ipilimumab: Aslaug Helland
*
Volrustomig: AstraZeneca
*
OT-101: Oncotelic Inc.
*
Lenvatinib: Hyogo Medical University
*
rAd-IFN: Trizell Ltd
*
RSO-021: RS Oncology LLC
*
VT3989: Vivace Therapeutics, Inc
*
gavo-cel: TCR2 Therapeutics
*
THOR-707: Sanofi
*
T3011: ImmVira Pharma Co. Ltd
*
TC-510: TCR2 Therapeutics
*
CTX131: CRISPR Therapeutics
*
PM8002: Biotheus Inc.
Mesothelioma Route of Administration
Mesothelioma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs, such as
*
Oral
*
Parenteral
*
Intravenous
*
Subcutaneous
*
Topical
Mesothelioma Molecule Type
Mesothelioma Products have been categorized under various Molecule types, such as
*
Recombinant fusion proteins
*
Small molecule
*
Monoclonal antibody
*
Peptide
*
Polymer
*
Gene therapy
Mesothelioma Pipeline Therapeutics Assessment
*
Mesothelioma Assessment by Product Type
*
Mesothelioma By Stage and Product Type
*
Mesothelioma Assessment by Route of Administration
*
Mesothelioma By Stage and Route of Administration
*
Mesothelioma Assessment by Molecule Type
*
Mesothelioma by Stage and Molecule Type
DelveInsight's Mesothelioma Report covers around 50+ products under different phases of clinical development like
*
Late-stage products (Phase III)
*
Mid-stage products (Phase II)
*
Early-stage product (Phase I)
*
Pre-clinical and Discovery stage candidates
*
Discontinued & Inactive candidates
*
Route of Administration
Further Mesothelioma product details are provided in the report. Download the Mesothelioma pipeline report to learn more about the emerging Mesothelioma therapies [https://www.delveinsight.com/sample-request/mesothelioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gaurav]
Some of the key companies in the Mesothelioma Therapeutics Market include:
Key companies developing therapies for Mesothelioma are - Merck & Co., Inc., Bristol-Myers Squibb, AstraZeneca, Roche, Novartis, Pfizer Inc., Eli Lilly and Company, Johnson & Johnson, GlaxoSmithKline plc (GSK), AbbVie Inc., Sanofi, and others.
Mesothelioma Pipeline Analysis:
*
The Mesothelioma pipeline report provides insights into
*
The report provides detailed insights about companies that are developing therapies for the treatment of Mesothelioma with aggregate therapies developed by each company for the same.
*
It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Mesothelioma Treatment.
*
Mesothelioma key companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
*
Mesothelioma Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
*
Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Mesothelioma market.
The report is built using data and information traced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations, and featured press releases from company/university websites and industry-specific third-party sources, etc.
Download Sample PDF Report to know more about Mesothelioma drugs and therapies [https://www.delveinsight.com/sample-request/mesothelioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gaurav]
Mesothelioma Pipeline Market Drivers
*
Rising incidence of malignant pleural mesothelioma due to historical asbestos exposure worldwide.
*
Increasing focus on immunotherapy, including immune checkpoint inhibitors, CAR-T cell therapies, and mesothelin-targeted treatments.
*
Strong pipeline of targeted therapies, gene therapies, and personalized medicine approaches aimed at improving patient outcomes.
*
Growing number of clinical trials supported by regulatory incentives such as Orphan Drug, Fast Track, and Breakthrough Therapy designations.
Mesothelioma Pipeline Market Barriers
*
Low disease prevalence limits patient recruitment and slows clinical trial enrollment.
*
Late-stage diagnosis and aggressive disease progression reduce the treatment window and clinical trial participation.
*
High development costs and lengthy clinical timelines for rare oncology therapies.
*
Limited understanding of mesothelioma biology and tumor heterogeneity complicates drug development.
*
Difficulty demonstrating significant survival benefits in clinical studies due to small patient populations.
Scope of Mesothelioma Pipeline Drug Insight
*
Coverage: Global
*
Key Mesothelioma Companies: The Netherlands Cancer Institute, Bristol-Myers Squibb, PrECOG, LLC., Memorial Sloan Kettering Cancer Center, ETOP IBCSG Partners Foundation, MedImmune LLC, Aslaug Helland, AstraZeneca, Oncotelic Inc., Hyogo Medical University, Trizell Ltd, RS Oncology LLC, Vivace Therapeutics, Inc, TCR2 Therapeutics, Sanofi, ImmVira Pharma Co. Ltd, TCR2 Therapeutics, CRISPR Therapeutics, Biotheus Inc., and others
*
Key Mesothelioma Therapies: Pembrolizumab, Nivolumab, Durvalumab, Sacituzumab govitecan-hziy, Carboplatin, Tremelimumab, ipilimumab, Volrustomig, OT-101, Lenvatinib, rAd-IFN, RSO-021, VT3989, gavo-cel, THOR-707, T3011, TC-510, CTX131, PM8002, and others
*
Mesothelioma Therapeutic Assessment: Mesothelioma current marketed and Mesothelioma emerging therapies
*
Mesothelioma Market Dynamics: Mesothelioma market drivers and Mesothelioma market barriers
Request for Sample PDF Report for Mesothelioma Pipeline Assessment and clinical trials [https://www.delveinsight.com/sample-request/mesothelioma-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gaurav]
Table of Contents
1. Mesothelioma Report Introduction
2. Mesothelioma Executive Summary
3. Mesothelioma Overview
4. Mesothelioma- Analytical Perspective In-depth Commercial Assessment
5. Mesothelioma Pipeline Therapeutics
6. Mesothelioma Late Stage Products (Phase II/III)
7. Mesothelioma Mid Stage Products (Phase II)
8. Mesothelioma Early Stage Products (Phase I)
9. Mesothelioma Preclinical Stage Products
10. Mesothelioma Therapeutics Assessment
11. Mesothelioma Inactive Products
12. Company-University Collaborations (Licensing/Partnering) Analysis
13. Mesothelioma Key Companies
14. Mesothelioma Key Products
15. Mesothelioma Unmet Needs
16 . Mesothelioma Market Drivers and Barriers
17. Mesothelioma Future Perspectives and Conclusion
18. Mesothelioma Analyst Views
19. Appendix
20. About DelveInsight
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance. It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=mesothelioma-pipeline-2026-moa-roa-fdaapproved-drugs-and-clinical-trial-progress-assessment-by-delveinsight-gsk-merck-bristolmyers-squibb-astrazeneca-roche-novartis-pfizer-inc]
Phone: +14699457679 Source: https://www.delveinsight.com/report-store.php
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Mesothelioma Pipeline 2026: MOA, ROA, FDA-Approved Drugs, and Clinical Trial Progress Assessment by DelveInsight | GSK, Merck, Bristol-Myers Squibb, AstraZeneca, Roche, Novartis, Pfizer Inc here
News-ID: 4568077 • Views: …
More Releases from ABNewswire
Compass Fence Co. Stands Among Fencing Companies Minneapolis Homeowners Call for …
Compass Fence Co. is a Twin Cities fencing contractor offering fence repair, installation, and replacement. Serving Minneapolis and surrounding counties, the family-owned company handles chain link, vinyl, and ornamental fences.
Homeowners across the Twin Cities area are paying closer attention to the condition of their fences, and the demand for reliable fencing companies Minneapolis [https://www.google.com/maps/place/Compass+Fence+Cofencing+companies+minneapolis/@45.048548,-93.2271118,111892m/data=!3m1!1e3!4m6!3m5!1s0x4de8b3f5c32f22c3:0x67dfe17641fb0b4!8m2!3d45.1716723!4d-93.0397957!16s%2Fg%2F11kbl99kzr!5m1!1e3?entry=ttu&g_ep=EgoyMDI2MDYyOS4wIKXMDSoASAFQAw%3D%3D] residents can count on has grown steadily. Compass Fence Co., a family-owned fencing contractor serving Minneapolis…
How Long Does It Take to Get Deck Permit Approval in Brooklyn Park? A Brooklyn P …
Exteriors Unlimited Inc. explains Brooklyn Park deck permit timelines, noting approvals typically take one to four weeks, with delays often tied to incomplete applications and inspection scheduling.
Homeowners planning a deck addition in Brooklyn Park often run into the same early obstacle: figuring out how long the permit process actually takes before deck construction can begin. The timeline is not always straightforward, and delays tied to incomplete applications, missing documentation, or…
Top Asset Managers in Singapore (2026) Report Published by Metaclade Research
Metaclade Research Publishes Its Latest Research Report Recognizing the Top Asset Managers in Singapore (2026)
Metaclade Research has published its latest market research report, "Top Asset Managers in Singapore [https://metaclade.com/top-asset-managers-in-singapore-2026]," offering an in-depth examination of the asset managers shaping the city-state's position as Asia's asset management capital.
The report evaluates leading asset managers based on investment performance, platform breadth and capability, pan-Asian reach, institutional quality, client alignment and franchise strength, and innovation…
As Labor Challenges Persist, Agricultural Drones Gain Ground Across U.S. Farms
As U.S. agriculture faces persistent labor shortages and rising operational costs, agricultural drones are becoming an increasingly important tool for improving efficiency and precision. The article explores how companies like VECTORAGR are driving adoption through localized partnerships, research collaborations, and advanced drone technologies, highlighting how automation is helping reshape modern farming while supporting the long-term evolution of precision agriculture in the United States.
Across the American agricultural landscape, the pressures facing…
More Releases for Mesothelioma
Mesothelioma Pipeline Outlook Report 2024 (Updated)
DelveInsight's, "Mesothelioma Pipeline Insight 2024" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in Mesothelioma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Key Takeaways from the Mesothelioma Pipeline Report
• DelveInsight's Mesothelioma pipeline report depicts a…
Mesothelioma Resource Centre Introduced the All Legal Rights and Options Platfor …
Mesothelioma Resource Centre announced the platform for all legal rights and options of Asbestos & Mesothelioma. It is the legal and health resources center for all sufferers of mesothelioma cancer, a cancer almost always caused by exposure to asbestos.
Generally, a mesothelioma victim must immediately seek redress once diagnosed with the cancer because if the disease has been established to be work-related and the responsible company is identified, a mesothelioma…
New Mesothelioma Treatment Technique Developed
Extrapleural pneumonectomy, a surgical procedure that removes mesothelioma cancer from the lining of the lung, has been reported to be an effective new mesothelioma treatment technique. The technique was developed by Dr. Sugarbaker, the co-leader of the Brigham Biomedical Research Institute's Cancer Research Center, Chief of the Institute's Division of Thoracic Surgery and a Professor of Oncologic Surgery at Harvard Medical School.
The surgical technique was applied on a mesothelioma patient…
Mesothelioma Cancer: Possible Treatment Option
An experiment carried out in Memorial Sloan-Kettering Cancer Center, Mount Sinai School of Medicine and the Medical University Vienna has tested the effectiveness of a genetically modified virus to treat mesothelioma in animals. The virus is known as Newcastle Disease Virus (NDV). Animals with mesothelioma administered with multiple doses of NDV responded better than those that received a single dose.
The use of a genetically engineered virus to disrupt the function…
Veteran Passed Away from Mesothelioma Cancer
It has been reported that a U.S. Army veteran passed away at the age of 64 from the asbestos cancer, malignant mesothelioma. He retired from the U.S. Army Corps of Engineers after 25 years of service. Prior to his military career, he worked at a steel company. It is likely that his mesothelioma was caused by asbestos exposure that he encountered at the steel company and during military service.
Malignant mesothelioma…
Weitz & Luxenberg Mesothelioma Lawyers win $1.28 Million Settlement in Mesotheli …
Weitz & Luxenberg mesothelioma lawyers recently secured a $1.28 million settlement for a 77-year-old former carpenter suffering from the asbestos cancer, mesothelioma. Prior to this settlement, Weitz & Luxenberg obtained $842,000 from another defendant.
The former carpenter is the father of six children and devoted his 30-year career to beautifying such New York City landmarks as Yankee Stadium and the Empire State Building. He was diagnosed with mesothelioma in…
